Company Filing History:
Years Active: 2010
Title: Barbara Scheiber-Mojdehkar: Innovator in Friedreich's Ataxia Treatment
In the realm of medical advancements, Barbara Scheiber-Mojdehkar emerges as a significant figure, contributing to the treatment of neurodegenerative diseases. Based in Vienna, Austria, she has dedicated her research to enhancing therapeutic strategies for conditions related to Friedreich's ataxia.
Latest Patents
Barbara holds a pivotal patent titled “Method for increasing frataxin expression.” This innovative approach utilizes human erythropoietin or its derivatives, which possess the biological activity of human erythropoietin, to enhance frataxin expression. The application of this method is particularly aimed at developing pharmaceutical preparations for the treatment of Friedreich's ataxia and related diseases.
Career Highlights
Barbara's career is marked by her role at the Medical University of Vienna, where she has conducted extensive research in her field. Her efforts have been instrumental in identifying new methods that could potentially transform treatment options for patients suffering from Friedreich's ataxia.
Collaborations
Throughout her professional journey, Barbara has collaborated with her coworker, Brigitte Nina Sturm. Together, they are contributing to the scientific community's understanding of Friedreich's ataxia and working towards innovative solutions that address the challenges posed by this condition.
Conclusion
Barbara Scheiber-Mojdehkar's innovative work in increasing frataxin expression stands as a testament to her commitment to advancing medical science. Her contributions could pave the way for new therapeutic avenues in the treatment of Friedreich's ataxia, highlighting the vital role of research in addressing complex health issues.